Literature DB >> 10027686

TAK-147, an acetylcholinesterase inhibitor, increases choline acetyltransferase activity in cultured rat septal cholinergic neurons.

K Kato1, H Hayako, Y Ishihara, S Marui, M Iwane, M Miyamoto.   

Abstract

TAK-147, a potent acetylcholinesterase (AChE) inhibitor, potentiated choline acetyltransferase (ChAT) activity in cultured rat septal cholinergic neurons in a concentration-dependent manner with an EC50 value of 4.47 nM. Donepezil, another potent AChE inhibitor, also increased ChAT activity although its potency was less than that of TAK-147. Other AChE inhibitors (rivastigmine, tacrine, physostigmine and neostigmine) showed no effect. The effects of TAK-147 were greater in the presence of NGF, suggesting a synergistic action of TAK-147 and NGF. TAK-147 and donepezil showed high affinity for sigma receptors, whereas tacrine and physostigmine did not. Haloperidol and ifenprodil, high-affinity sigma ligands, potently enhanced ChAT activity in the septal neurons. These results suggest that TAK-147 may have neurotrophic activity on central cholinergic neurons, not via AChE inhibition but possibly via an effect on tau receptors.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10027686     DOI: 10.1016/s0304-3940(98)00943-4

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  19 in total

1.  Donepezil in a narrow concentration range augments control and impaired by beta-amyloid peptide hippocampal LTP in NMDAR-independent manner.

Authors:  Nadezhda A Kapai; Julia V Bukanova; Elena I Solntseva; Vladimir G Skrebitsky
Journal:  Cell Mol Neurobiol       Date:  2011-10-04       Impact factor: 5.046

Review 2.  Sigma receptors: potential targets for a new class of antidepressant drug.

Authors:  James A Fishback; Matthew J Robson; Yan-Tong Xu; Rae R Matsumoto
Journal:  Pharmacol Ther       Date:  2010-05-11       Impact factor: 12.310

3.  Cognitive deficit associated with cholinergic and nerve growth factor down-regulation in experimental allergic encephalomyelitis in rats.

Authors:  Giulia D'Intino; Michela Paradisi; Mercedes Fernandez; Alessandro Giuliani; Luigi Aloe; Luciana Giardino; Laura Calzà
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-14       Impact factor: 11.205

4.  Dose-dependent sigma-1 receptor occupancy by donepezil in rat brain can be assessed with (11)C-SA4503 and microPET.

Authors:  Nisha K Ramakrishnan; Anniek K D Visser; Marianne Schepers; Gert Luurtsema; Csaba J Nyakas; Philip H Elsinga; Kiichi Ishiwata; Rudi A J O Dierckx; Aren van Waarde
Journal:  Psychopharmacology (Berl)       Date:  2014-03-18       Impact factor: 4.530

5.  The anti-amnesic and neuroprotective effects of donepezil against amyloid beta25-35 peptide-induced toxicity in mice involve an interaction with the sigma1 receptor.

Authors:  J Meunier; J Ieni; T Maurice
Journal:  Br J Pharmacol       Date:  2006-10-23       Impact factor: 8.739

6.  Synthesis of Novel 3-Aryl-N-Methyl-1,2,5,6-Tetrahydropyridine Derivatives by Suzuki coupling: As Acetyl Cholinesterase Inhibitors.

Authors:  S B Benaka Prasad; Y C Sunil Kumar; C S Ananda Kumar; C T Sadashiva; K Vinaya; K S Rangappa
Journal:  Open Med Chem J       Date:  2007-09-05

Review 7.  The pharmacology of sigma-1 receptors.

Authors:  Tangui Maurice; Tsung-Ping Su
Journal:  Pharmacol Ther       Date:  2009-07-18       Impact factor: 12.310

8.  In vivo visualization of donepezil binding in the brain of patients with Alzheimer's disease.

Authors:  Nobuyuki Okamura; Yoshihito Funaki; Manabu Tashiro; Motohisa Kato; Yoichi Ishikawa; Masahiro Maruyama; Hiroyasu Ishikawa; Kenichi Meguro; Ren Iwata; Kazuhiko Yanai
Journal:  Br J Clin Pharmacol       Date:  2007-12-07       Impact factor: 4.335

9.  Cognitive evaluation of disease-modifying efficacy of donepezil in the APP23 mouse model for Alzheimer's disease.

Authors:  Debby Van Dam; Katrien Coen; Peter Paul De Deyn
Journal:  Psychopharmacology (Berl)       Date:  2007-11-16       Impact factor: 4.530

10.  Pharmacology and therapeutic potential of sigma(1) receptor ligands.

Authors:  E J Cobos; J M Entrena; F R Nieto; C M Cendán; E Del Pozo
Journal:  Curr Neuropharmacol       Date:  2008-12       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.